Sentence examples for mutations might confer from inspiring English sources

Escape mutations might confer reduced viral fitness by coincidentally increasing epitope processing (Tenzer et al., 2009) and/or reducing viral replication or infectivity (Goulder and Walker, 2012).

These mutations might confer high virulence to the virus by enhancing replication efficiency, increasing polymerase activity and disease severity of avian influenza viruses in mammals (37 ).

In this case, the Apert mutations might confer a dominant-negative functional effect on FGFR2-IIIb in human palatal epithelia, resulting in failure of fusion of the palatal shelves (Britto et al., 2002).

Intriguingly, the suppression of genome instability in the context of replication stalling amid dysfunctional SMC-5/ 6 suggests that the maintenance of familial BRCA1 carrier mutations might confer selective advantages under certain conditions of genotoxic challenges.

PI3KCA mutations are common in breast cancer and these mutations might confer the sensitivity to inhibitors as anti-EGFR or anti-AKT1, although the relationship of PI3KCA mutations and prognosis of breast cancer patients has not been unequivocally reported.

This was among the most important developments in personalised mCRC management in recent years.> Continued investigation of the molecular mechanisms underpinning tumour development and growth in mCRC led to the hypothesis that, even with a KRAS exon 2 WT population, other mutations might confer resistance to EGFR inhibitors.

"The results indicate that the mutation might confer a preference for alcohol," Gochman said.

Fourth, an early mutation might confer the potential to metastasize, but that potential may only be activated by a later mutation [2].

Interestingly, the E253K mutation might confer deficiency in ATP hydrolysis similar to previously reported kinesin-1 E236A rigor mutation 36 (see Fig. S2 for sequence alignment of E253 and E236).

To prospectively identify AR mutations that might confer resistance to enzalutamide, we performed a reporter-based mutagenesis screen and identified a novel mutation, F876L, which converted enzalutamide into an AR agonist.

We also searched for PfRpL4 mutations that might confer P. falciparum AZT resistance.